A study to compare the effect of Levobupivacaine and Ropivacaine given in thoracic paravertebral space in Modified Radical Mastectomy patients

Comparative Randomized Double Blind Study of thoracic Paravertebral Block with Levobupivacaine 0.375% and Ropivacaine 0.375% in Modified Radical Mastectomy - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/09/045477

Enrollment

Registered

2022-09-13

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50-C50- Malignant neoplasms of breast

Interventions

Intervention1: Inj.Levobupivacaine 0.375%: Inj Levobupivacaine 0.375% is to be given at dose 5 ml in each thoracic paravertebral space T3-T6. Control Intervention1: Inj.Ropivacaine 0.375%: Inj Ropiva

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients belonging to ASA Grade I and ASA Grade II. 2) Patients scheduled for elective surgery for modified radical mastectomy under thoracic paravertebral block.

Exclusion criteria

Exclusion criteria: 1) Patient refusal to consent. 2) ASA Physical status more than II. 3) Patients with labile blood pressure, severe renal, endocrine and cardiac dysfunction, heart block, bleeding disorder, psychiatry disease. 4) Morbidly obese patients. 5) Patients with history of allergy to study drug.

Design outcomes

Secondary

Measure	Time frame
NILTimepoint: NA	—

Primary

Measure	Time frame
Pain score in Visual Analogue ScaleTimepoint: just after extubation, and after 30minutes, 1 hour,6 hour and 24 hour after extubation	—

Countries

India

Contacts

Public ContactDr Nirmala Majee

Bankura Sammilani Medical College

dr.majeenirmala@gmail.com9933753059

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026